Allergen Labelling Red Flags When a Value Line Is Being Quoted

Key takeaways

1. The most reliable red flag is an answer that describes certificates when the question asked for which declarable substances are present above threshold.
2. A quotation that prices the product without ever asking about the intended market is not really a compliance-aware quotation.
3. Refusal to state who supplies the fragrance compound is a structural risk, because that supplier controls the allergen data the brand needs.
4. A very short turnaround offered at a very low price often assumes that documentation work will happen after the order, which is exactly when it becomes expensive.
5. Weak answers on allergen data usually predict weak answers on other technical questions, so the signal is worth generalising.

Value lines attract a particular kind of sourcing conversation. The volumes are modest, the price expectation is sharp, and both sides want to keep the process short. That pressure is precisely what makes allergen labelling a useful lens: it is a question with a factual answer, it cannot be bluffed for long, and the quality of the response reveals how the supplier manages information in general.

Regulation (EU) 2023/1545 expanded the list of fragrance allergens requiring on-pack disclosure and set deadlines for placing products on the EU market and for making existing stock available ^[1]. The practical consequence for a buyer is that the allergen question is now a live one for every fragrance product sold into that market, including entry-price ranges that were previously sold with a very short ingredient list.

The signal is usually a missing answer, not a wrong one

It is rare for a supplier to state a false allergen position. It is common for the question to be deflected into a neighbouring topic: the factory holds this certification, the compound comes from a reputable house, the product has been sold in Europe for years. Each of those may be true and none of them answers the question, which is which declarable substances are present above the applicable threshold in this specific compound.

The deflection is not always dishonest. Many factories genuinely do not hold composition data for compounds they buy in, and their answer reflects what they have rather than a decision to conceal. The distinction matters, because a supplier that does not hold the data but knows who does is a workable partner, while a supplier that cannot name the source at all is not. The European Commission's own material on cosmetic safety requirements is a reasonable primer for what a buyer is entitled to ask about ^[2].

One more layer: allergen restrictions and labelling are not the same question. Whether a material may be used at all is a formulation matter governed by industry standards, while whether it must be declared is a labelling matter. A supplier that conflates the two is telling the buyer that nobody has separated those files.

Six signals and what they usually mean

None of these signals is fatal on its own. Two or three of them in the same conversation usually mean the brand will be doing the compliance work itself, with no leverage, after the packaging has been ordered.

Red flags that are really about the paper trail

Compliance failures on value lines are usually version failures. The label was correct when it was written, then the compound changed, or the fill volume changed, or the product moved from a rinse-off to a leave-on claim, and nobody revisited the declaration. A supplier that cannot describe how changes are recorded is a supplier that will produce this failure eventually.

The question to ask is deliberately concrete: if a raw material in this compound is substituted next year, what happens to the ingredient list, who decides, and will we be told? A vague answer about quality management is a red flag. A specific answer about a change note, a re-read of the allergen position and a written notice to the brand is not. A partner's its background and certifications is worth reading in that light, as evidence of process rather than as a badge.

The same logic applies to retention. If a question about a batch arises eighteen months after shipment, the answer should come from a retained sample and a batch record rather than from recollection. That expectation belongs in the supply agreement, not in a conversation after the problem.

When the red flag is on the buyer's side of the table

Buyers create allergen problems too, and the most common one is briefing late. A brand that chooses a bottle, orders cartons, books a photographer and only then asks about the ingredient list has given away every option it had. The second is briefing vaguely, asking for a scent that smells like a well-known reference without saying which market it will be sold in.

There is also the false economy of the cheapest sample route. A free sample with no documentation is not cheaper than a paid sample with a declarable substance statement, because the missing document gets bought later at a much higher price. Comparing candidates on how to compare perfume factories is more useful than comparing them on sample price alone. A brand that works with Xuelei should expect the documentation question to be handled as routine work, not as a favour granted after the order.

Three questions that reframe the whole conversation

Which substances in this compound are above the declaration threshold, and can that be confirmed in writing with the sample? Who supplies the compound, and can we see the technical data sheet? If the formulation changes, how will we be told and what happens to the label? These three questions cost nothing to ask and separate serious partners from order-takers very quickly.

What a defensible answer actually looks like

A good answer is short, specific and dated. It names the substances, references the threshold basis, identifies the person who signed it and says when the data was last reviewed. It does not need to be long, and on a simple fragrance it may be a single line stating that no listed substance is present above the applicable threshold. What makes it defensible is that somebody owns it.

A second marker of a serious supplier is knowing the limits of its own answer. The scientific committee that advises the European Commission on consumer safety publishes opinions that can lead to future changes in restrictions and labelling ^[3], and a supplier that tracks that pipeline is displaying exactly the habit a brand wants. Markets outside the EU move on their own timetables as well, and a manufacturer that sells across markets will normally maintain parallel documentation; Health Canada, for example, publishes its own cosmetic safety material for industry and consumers ^[4].

Finally, the answer should be reproducible. A brand that receives a clear allergen position for one compound should expect the same format for the next one, without renegotiating. That consistency is a better indicator of a working relationship than any single document, and it is the kind of thing a buyer can check before the first order by looking at how a manufacturer presents its service scope. Xuelei's official website describes the manufacturing and documentation side of that work, and it is a fair test of whether the words match the questions above.

Frequently asked questions